

A Genetic Survey of Fluoxetine Action on Synaptic Transmission in *Caenorhabditis elegans*

Andrey Kullyev,^{*,1} Catherine M. Dempsey,^{*,†,1} Sarah Miller,[‡] Chih-Jen Kuan,^{*} Vera M. Hapiak,[‡] Richard W. Komuniecki,[‡] Christine T. Griffin[†] and Ji Ying Sze^{*,2}

^{*}Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461 [†]Department of Biology, National University of Ireland, Maynooth, County Kildare, Ireland [‡]Department of Biological Sciences, University of Toledo, Toledo, Ohio 43606

Manuscript received May 13, 2010
Accepted for publication August 13, 2010

ABSTRACT

Fluoxetine is one of the most commonly prescribed medications for many behavioral and neurological disorders. Fluoxetine acts primarily as an inhibitor of the serotonin reuptake transporter (SERT) to block the removal of serotonin from the synaptic cleft, thereby enhancing serotonin signals. While the effects of fluoxetine on behavior are firmly established, debate is ongoing whether inhibition of serotonin reuptake is a sufficient explanation for its therapeutic action. Here, we provide evidence of two additional aspects of fluoxetine action through genetic analyses in *Caenorhabditis elegans*. We show that fluoxetine treatment and null mutation in the sole SERT gene *mod-5* eliminate serotonin in specific neurons. These neurons do not synthesize serotonin but import extracellular serotonin via MOD-5/SERT. Furthermore, we show that fluoxetine acts independently of MOD-5/SERT to regulate discrete properties of acetylcholine (ACh), gamma-aminobutyric acid (GABA), and glutamate neurotransmission in the locomotory circuit. We identified that two G-protein-coupled 5-HT receptors, *SER-7* and *SER-5*, antagonistically regulate the effects of fluoxetine and that fluoxetine binds to *SER-7*. Epistatic analyses suggest that *SER-7* and *SER-5* act upstream of AMPA receptor *GLR-1* signaling. Our work provides genetic evidence that fluoxetine may influence neuronal functions and behavior by directly targeting serotonin receptors.

FLUOXETINE is a selective serotonin reuptake inhibitor (SSRI) and has made a major impact on the treatment of many behavioral disorders. The empirical action of SSRIs is blocking the serotonin reuptake transporter (SERT). SERT is localized in the plasma membrane and transports extracellular serotonin (5-HT) into the cytoplasm (BLAKELY *et al.* 1991; HOFFMAN *et al.* 1991), this being the major mechanism of terminating 5-HT signaling. Consequently, SSRIs are thought to exert therapeutic effects by blocking SERT from removal of 5-HT in the synaptic cleft, thereby increasing the level of 5-HT signals (SCHATZBERG and NEMEROFF 2004). However, several observations point to additional actions of SSRIs on the 5-HT system and neuronal functions. First, knockout of SERT in mouse caused a marked reduction of 5-HT in the brain (BENGEL *et al.* 1998). Second, a variety of studies with cultured mammalian cells and mouse brain slices showed that SSRIs and tricyclic antidepressant agents (TCAs) have high affinities to many 5-HT receptor

subtypes and act as agonists or antagonists depending on particular receptors being tested (NI and MILEDI 1997; KROEZE and ROTH 1998; EISENSAMER *et al.* 2003). Third, genetic analyses of the nematode *Caenorhabditis elegans* in our laboratory and others showed that fluoxetine and the TCA imipramine (Tofrani) could influence behavior independent of SERT function (WEINSHENKER *et al.* 1995; RANGANATHAN *et al.* 2001; DEMPSEY *et al.* 2005). In this study, we carried out a systematic survey of SSRIs treatment in *C. elegans* to gain new insights into actions of SSRIs on the 5-HT system and other neurotransmitter systems.

In both vertebrates and invertebrates, 5-HT functions as a neuromodulator to either facilitate or inhibit synaptic transmission of other neurotransmitters (FINK and GOTHERT 2007). Modulation of synaptic activity by 5-HT signaling underscores the synaptic plasticity involved in stress responses, learning, adaptation, and memory (KANDEL 2001; ZHANG *et al.* 2005). The role of 5-HT in *C. elegans* was initially identified through pharmacological experiments showing that exogenous 5-HT can promptly induce changes in a variety of behaviors, including feeding, egg laying, and locomotion (AVERY and HORVITZ 1990; WEINSHENKER *et al.* 1995; NURRISH *et al.* 1999). The relevance of these behaviors to endogenous 5-HT has since been validated

Supporting information is available online at <http://www.genetics.org/cgi/content/full/genetics.110.118877/DC1>.

¹These authors contributed equally to this work.

²Corresponding author: 202 Golding Bldg., 1300 Morris Park Ave., Bronx, NY 10461. E-mail: jiying.sze@einstein.yu.edu

through studies of mutants of 5-HT signaling. Importantly, multiple 5-HT receptors may function in distinct cells synergistically or antagonistically to regulate a specific behavior (CARNELL *et al.* 2005; DERNOVICI *et al.* 2007; MURAKAMI and MURAKAMI 2007; HAPIAK *et al.* 2009). In nearly all tested paradigms, fluoxetine and imipramine induce behavioral changes similarly to exogenous 5-HT (WEINSHENKER *et al.* 1995; NURRISH *et al.* 1999), implying that fluoxetine regulates 5-HT inputs to these neural circuits. However, the tryptophan hydroxylase gene *tph-1* is required for 5-HT biosynthesis in *C. elegans* (SZE *et al.* 2000), *mod-5* encodes its sole SERT (RANGANATHAN *et al.* 2001), and yet fluoxetine could stimulate egg laying and inhibit locomotion in *mod-5* and *tph-1* mutants (WEINSHENKER *et al.* 1995; CHOY and THOMAS 1999; RANGANATHAN *et al.* 2001; DEMPSEY *et al.* 2005). These findings provided a basis for further investigation into genes and synaptic functions regulated by 5-HT and the impact of fluoxetine on 5-HT signaling.

Here we present genetic evidence of multifaceted effects of fluoxetine on the 5-HT system and its downstream targets in *C. elegans*. We show that fluoxetine treatment and loss of MOD-5/SERT function do not simply increase presynaptic 5-HT signals. Rather, they may eliminate 5-HT in specific neurons. Furthermore, fluoxetine acts independently of SERT to regulate 5-HT serotonin receptors and their downstream targets involved in acetylcholine (ACh), gamma-aminobutyric acid (GABA), and glutamate neurotransmission.

MATERIALS AND METHODS

Strains: The maintenance of *C. elegans* strains, nematode growth media (NGM), and standard buffers (M9, S-basal, and S-medium) used to handle worms have been described (BRENNER 1974). Wild type (WT) was the Bristol strain N2. Mutant strains used were as follows: *dop-6(ok2090)*, *cha-1(p1152)*, *pha-1(e2123);mdlIs18[Punc-17::GFP;pha-1(+)]* (*ACh::gfp*) (from J. Rand, University of Oklahoma Health Sciences Center, Oklahoma City, OK), *eat-4(ad572)*, *eat-4(n2474)*, *glr-1(n2461)*, *KP987 lin-15B(n765) nuls1 X[lin-15(+)]*; *PV6 glr-1::GFP*; *mod-5(n3314)*, *mod-5(n822)* (from R. Horvitz, Massachusetts Institute of Technology, Cambridge, MA), *mod-1(ok103)*, *myo-3(st386);stEx30 [Pmyo-3::GFP;rol-6(su1006)]* (MYO-3::GFP), *nrf-6(sa525)*, *ser-1(ok345)*, *ser-3(ok1995)*, *ser-3(ad1774)*, *ser-3(ok2007)*, *ser-4(ok512)*, *ser-5(tm2654)*, *ser-5(tm2647)*, *ser-7(tm1325)*, *ser-7(tm1548)*, *ser-7(tm1728)*, *slo-1(js379)*, *slo-1(ky399)*, *tag-24(ok371)*, *tom-1(ok285)*, *tph-1(mg280)*, *unc-25(e156)*, *unc-29(e193)*, *unc-43(e408)*, *unc-43(n498)*, *unc-49(e407)*, and EG1653 (*lin-15(n765ts)*; *oxIs22[pEK(lin-15 +)]*; *UNC-49B::GFP*) (from E. Jorgensen, University of Utah, Salt Lake City, UT).

Constructions of *ser-5(+)* and *ser-7(+)* transgenes: The constructs were generated by PCR, and purified PCR products were used to generate transgenic worms. *elt-2::gfp*, which is expressed in the gut (FUKUSHIGE *et al.* 1999), was used as a transgenic marker. *ser-5(+)* was a genomic fragment amplified from the WT genome encompassing a 6305-bp 5'-upstream promoter sequence, exons/introns, and a 1118-bp 3'-untranslated

region (UTR) of the *ser-5* gene. *ser-7(+)* was a genomic fragment containing a 1858-bp 5'-upstream promoter sequence, exons/introns, and a 174-bp 3'-UTR of the *ser-7* gene.

Indirect immunofluorescence histochemistry and microscopy: Whole-mount staining of *C. elegans* with anti-5-HT antibodies was performed as described previously (SZE *et al.* 2002). To analyze the effect of fluoxetine and imipramine on 5-HT immunoreactivity, the drugs were dissolved in water and the solution was poured onto NGM plates to give the final concentration of 0.4 mg/ml imipramine or 0.5 mg/ml fluoxetine. The plates were dried under a hood for 2–3 hr and used immediately. Well-fed mixed-staged worms were incubated on the drug plates overnight and then fixed for staining. The control animals were raised and stained in parallel but without drug treatment. Stained animals were viewed using an AxioImager Z1 microscope equipped with proper filters and an AxioCam MR digital camera (Zeiss, Northwood, NY).

Drug and behavioral assays: Sensitivity to fluoxetine and other SSRIs was scored by calculating the percentage of animals paralyzed after being incubated in a liquid medium containing a drug. In all experiments except that described in Figure 2, a and c, the assays were carried out in culture media containing food. Food used in this assay was *Escherichia coli* OP50. A single colony of the bacteria was inoculated in 250 ml of 2xYT medium with shaking at 37° overnight. The resulting bacteria were concentrated by centrifugation, and the pellet was resuspended in 3 ml of S-basal. Worms were washed off NGM plates with M9 and the number of worms in the suspension was adjusted to ~1000 worms/ml. Drug assays were carried out in 15 ml polypropylene conical tubes. Each assay contained 50 µl of the bacteria concentrate and 50 µl of the 1000/ml worm suspension in 2 ml of S-medium. Unless specified, the final concentrations of drugs in the media were 5 mg/ml 5-HT and 0.5 mg/ml fluoxetine. The number of immobile animals was scored following incubation on a rocking platform at 20°. The incubation time for fluoxetine assays was 24 hr unless indicated otherwise. Animals remaining completely immobile for 10 sec were recorded as paralyzed. WT and mutant strains were always assayed in parallel and the difference in the percentage of paralyzed WT and mutant animals was determined. Fluoxetine sensitivities of strains grown and assayed in parallel were compared.

In experiments described in Figure 2, a and c, worms were incubated in 5 mg/ml 5-HT or 0.5 mg/ml fluoxetine in M9 without food for 30–60 min and were then either transferred to NGM plates to recover or examined immediately.

Resistance to aldicarb-induced paralysis was assayed as described (NURRISH *et al.* 1999). Briefly, 20 1-day-old adults per strain were transferred onto a NGM plate containing 1 mM aldicarb, and the number of animals paralyzed on the plate was scored at various time points. An animal was scored as being paralyzed if no movement was detected after prodding with a platinum wire. To assay the inhibition of aldicarb effects by 5-HT and fluoxetine, animals were preincubated for 2 hr on plates containing 5-HT (5 mg/ml), fluoxetine (0.5 mg/ml), or no drug control, before being exposed to aldicarb.

Imaging analysis and quantification of GFP reporters: One-day-old young adult hermaphrodites were examined, unless specified otherwise. For evaluation of *ACh::gfp* expression level, images of the 9th and 10th ACh neurons along the ventral nerve cord were captured at a fixed exposure time of 150 ms to 100% UV level, and the fluorescence intensity over a 25 × 25-pixel area within a neuron was quantified, using Adobe Photoshop 7.0 software. For evaluation of the abundance of UNC-49::GFP, images along the ventral nerve cord were captured at a fixed exposure time of 300 ms and the

fluorescence intensity over a $50 \times 5\text{-}\mu\text{m}$ area as illustrated in Figure 3e was quantified using Image J software.

GLR-1::GFP was evaluated by counting the number of GFP puncta along the ventral cord in live, genotype-blinded animals under the fluorescence scope.

[^3H]Lysergic acid diethylamide (LSD) binding assays: The SER-7b expression vector and the binding assays with the membrane fraction of COS-7 cells expressing SER-7b have been published (HOBSON *et al.* 2003, 2006). Briefly, COS-7 cells were transiently transfected with the SER-7b expression construct for 48 hr. The transfected cells were harvested and lysed, and the membrane fraction of the lysate was collected after centrifugation. [^3H]LSD saturation binding and inhibition of [^3H]LSD binding by 5-HT and fluoxetine were assayed in a 100- μl reaction volume in a well of 96-well microtiter plates at room temperature. For saturation binding, the membrane extract containing 15 μg proteins was incubated for 1 hr in the dark with various concentrations of [^3H]LSD (1–50 nM) to obtain B_{max} and K_d values. To test the affinity of 5-HT and fluoxetine to SER-7b, the membrane extract was incubated with 10 nM [^3H]LSD and various concentrations of 5-HT and fluoxetine, determining the ability to replace [^3H]LSD binding. For both saturation and inhibition binding assays, non-specific bindings were evaluated by incubation of the reaction mixture with a 1000-fold excess of unlabeled LSD. The binding assays were terminated by filtration with GF/B filters (Perkin-Elmer, Wellesley, MA) previously soaked with 0.3% polyethyleneimine. The filters were washed three times with ice-cold TEM buffer and dried overnight, and the radioactivity was quantified by liquid scintillation counting. The binding data were analyzed by nonlinear regression analysis using DeltaGraph (DeltaGraph Version 4.0; DeltaPoint, Chicago).

Statistics: Statistical analyses were performed using Minitab 12.1 (Minitab Inc., 1998). For comparisons between two test groups, Student's *t*-tests were carried out. Comparisons between more than two groups used ANOVA (one-way) followed by a Tukey's pairwise multicomparison procedure. Results that could not be normalized were tested with nonparametric Mann–Whitney *U*-tests or Kruskal–Wallis tests.

RESULTS

Fluoxetine and mutations in *mod-5*/SERT eliminate 5-HT in specific neurons: In *C. elegans* 5-HT in specific neurons can be precisely discerned by whole-mount staining of the entire animal with antibodies raised against 5-HT. In WT larvae 5-HT immunoreactivity can be detected in four classes, a total of seven neurons in the head region (Figure 1a): a pair of the NSM secretory neurons, a pair of the ADF chemosensory neurons, and a pair of the AIM and the single RIH interneurons. In addition, 5-HT immunoreactivity can be detected in a pair of the HSN motorneurons in adults (Figure 1b). Mutants of the tryptophan hydroxylase gene *tph-1* showed no discernible 5-HT immunoreactivity (SZE *et al.* 2000), confirming the specificity of the antibodies to 5-HT. During the process of characterizing *tph-1* function, we found that a GFP reporter for the *tph-1* gene (*tph-1::gfp*) was expressed primarily only in the NSM, the ADF, and the adult HSN neurons (Figure 1, e and f) (SZE *et al.* 2000). Subsequently, it was reported that another essential enzyme for 5-HT synthesis, the *bas-1* decarboxylase, was not expressed in RIH (HARE




FIGURE 1.—Fluoxetine treatment and mutations in *mod-5*/SERT abolish anti-5-HT immunoreactivity in the RIH and AIM neurons. (a–d) Photomicrographs of animals stained with anti-5-HT antibodies. To test the effects of MOD-5/SERT inhibitors, WT animals were incubated overnight on NGM plates containing 0.5 mg/ml of fluoxetine (as shown) or 0.4 mg/ml of imipramine (not shown) before fixation for staining. (e and f) Photomicrographs of WT animals expressing *tph-1::gfp*. All the animals shown have anterior to the right.

and LOER 2004). One explanation for these results could be less efficient expression of the transgenes in the AIM and RIH neurons. Alternatively, AIMS and RIH do not synthesize 5-HT. To distinguish between these possibilities, we analyzed mutants of the sole SERT gene *mod-5*. In both the *mod-5(n3314)* deletion and *mod-5(n822)* opal mutants, we observed 5-HT immunoreactivity in NSMs, ADFs, and adult HSNs but not in AIMS and RIH (Figure 1c). We concluded that AIMS and RIH use MOD-5/SERT to absorb extracellular 5-HT, but do not synthesize it.

We therefore used 5-HT immunoreactivity in the AIM and RIH neurons as a measurement to assess the efficacy of MOD-5/SERT inhibitors in *C. elegans*. In WT animals incubated for 4 hr on culture plates containing 0.5 mg/ml fluoxetine or 0.4 mg/ml imipramine, 5-HT immunoreactivity in AIMS and RIH was substantially reduced (data not shown). 5-HT immunoreactivity in AIMS and RIH became undetectable in most animals following 24-hr drug treatments (Figure 1d). Relatively high drug concentrations are commonly used in experiments with *C. elegans* because drugs are supplied in growth media and only small amounts of a drug enter animals (LEWIS *et al.* 1980). It has been reported that in the CNS of rodents and humans SERT is expressed in many neurons that do not express the enzymes essential for 5-HT biosynthesis (D'AMATO *et al.* 1987; HOFFMAN *et al.* 1998; LEBRAND *et al.* 1998; VERNEY *et al.* 2002). Thus, in mammals as well as in *C. elegans* there are two distinctive populations of serotonergic neurons: neurons synthesizing

5-HT and neurons absorbing 5-HT from extracellular space. Our results indicate that for those 5-HT-absorbing neurons fluoxetine treatment may result in a reduction, rather than an increase, in 5-HT signals. This intriguing finding prompted us to further investigate the effects of SSRIs on neuronal functions regulated by 5-HT. The conditions for fluoxetine to inhibit 5-HT immunoreactivity in the AIM and RIH neurons were used as a guideline in studies described below.

A behavioral assay for genetic survey of fluoxetine action in living animals: The locomotory control circuit of *C. elegans* affords a simple paradigm for delineation of the genetic basis and molecular mechanisms of SSRIs on 5-HT downstream targets in a defined neural circuit. *C. elegans* locomotion is a reproducible behavior reflecting integrated signaling of multiple neurotransmitters and neuromodulators, including ACh, GABA, glutamate, neuropeptides, dopamine, and 5-HT. In either solid or liquid medium, *C. elegans* moves continuously in a sinuous fashion. It has been well established that 5-HT and fluoxetine inhibit locomotion (CHOY and THOMAS 1999; NURRISH *et al.* 1999). We reasoned, if we could identify the genes and locomotory properties regulated by 5-HT and fluoxetine, that may give us some clues to the actions of fluoxetine on 5-HT downstream targets.

In this study, we monitored *C. elegans* locomotion in liquid media because of the ease to recognize paralyzed worms in liquid. When bathed in liquid media containing 5-HT or fluoxetine, *C. elegans* stopped moving within 1 hr and the paralyzed animals could resume locomotion when they were immediately transferred to drug-free media (Figure 2a). Fluoxetine-induced paralysis was dose dependent (Figure 2b).

We next sought cellular markers correlating with paralysis induced by 5-HT and fluoxetine. *C. elegans* may become paralyzed either by hypercontraction of the body-wall muscles due to excessive stimulatory signaling or by hyperrelaxation due to a paucity of stimulatory signaling (REINER *et al.* 1995). To distinguish between these possibilities and to compare the effect of 5-HT and fluoxetine, we examined the body-wall muscle sarcomeres in living animals using GFP-tagged myosin heavy chain protein MYO-3 (MYO-3::GFP). In untreated animals the muscle fibers were interdigitated, reflecting a normal muscle contractile tone; however, in animals exposed to either 5-HT or fluoxetine for <1 hr the sarcomeres were elongated and muscle fibers were stretched apart, remaining parallel to each other and giving a relaxed appearance (Figure 2c). By contrast, animals treated with the cholinesterase inhibitor aldicarb, which causes hypercontraction of the body-wall muscles, showed densely packed muscle fibers (Figure 2c). Interestingly, animals incubated in media containing 5-HT for 4 hr became adapted to the drug and resumed muscle contractile tone, whereas the muscle fibers in animals incubated with fluoxetine remained relaxed (Figure 2c). Incidentally, animals exposed to

5-HT resumed locomotion, but animals exposed to fluoxetine remained paralyzed even after 24 hr and died. These results suggest that both 5-HT and fluoxetine caused profound body-wall muscle relaxation; however, their actions are not identical.

To test whether paralysis induced by fluoxetine is a result of inactivation of MOD-5/SERT, we analyzed *mod-5* mutants. The *mod-5(n3314)* and *mod-5(n822)* mutants grown on NGM plates exhibited superficially normal locomotion, as previously reported (RANGANATHAN *et al.* 2001). Both mutants remained sensitive to fluoxetine in the paralysis assay, although their sensitivities were slightly reduced compared to WT animals (Figure 2d). Furthermore, the *tph-1(mg280)* mutant was fully sensitive to fluoxetine-induced paralysis (Figure 2d). These results are in agreement with a published study (RANGANATHAN *et al.* 2001). MYO-3::GFP in untreated *mod-5* mutants was similar to that in WT animals, although the muscle fibers in the untreated *tph-1* mutant were often thicker and more branching (supporting information, Figure S1). Fluoxetine caused muscle relaxation in both *mod-5* and *tph-1* mutants (Figure S1).

To further characterize this fluoxetine assay, we tested mutants of type II calcium- and calmodulin-dependent protein kinase (CaMKII) *unc-43*. It has been reported that *unc-43* loss- and gain-of-function mutations cause, respectively, hypo- and hypercontraction of the body-wall muscles (REINER *et al.* 1995, 1999). Indeed, the *unc-43(n498)gf* mutant displayed densely packed MYO-3::GFP muscle fibers (Figure 2c). Fluoxetine did not cause muscle relaxation in the *unc-43gf* mutant, although the muscle fibers were packed less densely compared to untreated *unc-43gf* animals (Figure 2c). The *unc-43gf* mutant was more resistant, whereas the *unc-43(n409)lf* mutant was hypersensitive to fluoxetine-induced paralysis (Figure 2e). These results showed that the sensitivity to fluoxetine-induced paralysis could be influenced by a particular component in the locomotory system, suggesting that this assay may allow us to identify additional genes and functional pathways regulated by fluoxetine.

5-HT and fluoxetine regulate ACh, GABA, and glutamate neurotransmission: To characterize the impact of 5-HT and fluoxetine on synaptic transmission of the locomotory circuit, we examined ACh, GABA, and glutamate signaling in living *C. elegans*. We assayed ACh release at the body-wall neural muscular junctions (NMJs) by measuring the sensitivity to the acetylcholinesterase inhibitor aldicarb. Using GFP reporters, we analyzed the expression of genes involved in ACh, GABA, and glutamate neurotransmission and examined the morphology of the locomotory neurons. We also tested fluoxetine sensitivity in mutants of ACh, GABA, and glutamate neurotransmission, using the paralysis assay.

Aldicarb causes paralysis in *C. elegans* due to the accumulation of ACh at the body-wall NMJs and is




FIGURE 2.—Fluoxetine and 5-HT cause muscle relaxation. (a) The percentage of WT worms moving in M9 (open bar) and in M9 supplemented with 5 mg/ml 5-HT or 0.5 mg/ml fluoxetine (solid bars). The paralyzed animals resumed locomotion after they were transferred to standard culture plates (shaded bars). Each bar represents the mean of three independent experiments, each performed with three replicates \pm SEM. One-day-old adults were tested. (b) Dosage dependence of the paralytic effect of fluoxetine in WT animals. Larval stage four (L4) worms were incubated for 24 hr in liquid media without fluoxetine or containing fluoxetine at indicated concentrations. Each bar represents the mean of three independent experiments, each performed with three replicates \pm SEM. Different letters represent a significant difference (one-way ANOVA, $P < 0.05$). (c) Visualization of body-wall muscle sarcomeres in living *C. elegans*. WT animals expressing an integrated MYO-3::GFP transgene were incubated for 30 min or 4 hr in media without drug or supplemented with 5 mg/ml 5-HT, 0.5 mg/ml fluoxetine, or 0.8 mM aldicarb. One-day-old adults were examined. (d and e) Quantification of fluoxetine-induced paralysis in WT and mutants. Fluoxetine sensitivity was scored by calculating the percentage of worms paralyzed following 24-hr incubation in liquid media supplemented with 0.5 mg/ml fluoxetine. The values of each mutant strain are normalized to that of WT worms assayed in parallel. Each bar represents the mean of three independent experiments \pm SEM. * $P < 0.05$, ** $P < 0.01$, Student's *t*-test. In a and c, the assays were performed with animals in culture media without food, allowing fast ingestion of the drugs, and thus likely reflecting the maximal speed of drug effects. In b, d, e, and all other experiments described in this article the assays were performed with well-fed animals, reflecting optimal physiological conditions.

therefore frequently used to measure steady-state ACh release in living animals (MAHONEY *et al.* 2006). 5-HT and fluoxetine reduced the paralytic effect of aldicarb (Figure 3a), as previously reported (NURRISH *et al.* 1999). By contrast, 5-HT and fluoxetine did not inhibit sensitivity to levamisole, a specific agonist of the nicotinic ACh receptor UNC-29 in the body-wall muscles (data not shown) (NURRISH *et al.* 1999), suggesting that 5-HT regulates presynaptic ACh neurotransmission. We next examined a GFP reporter under the control of a common promoter element shared by the vesicular ACh transporter gene *unc-17* and the choline acetyltransferase gene *cha-1* (*ACh::gfp*) (ALFONSO

et al. 1994). 5-HT and fluoxetine did not cause any discernible changes in the morphology of cholinergic neurons, but they both reduced *ACh::gfp* expression. Following 2 hr exposure to either 5-HT or fluoxetine, there was a modest 10% reduction in GFP fluorescence in the ventral cord motorneurons, compared to age-matched, untreated controls (Student's *t*-test, $P < 0.05$ for 5-HT and $P < 0.06$ for fluoxetine, $N = 30$ per treatment). Twenty-four hours of exposure to fluoxetine resulted in an $\sim 30\%$ reduction in *ACh::gfp* intensity (Figure 3b). Fluoxetine also reduced aldicarb sensitivity and downregulated *ACh::gfp* expression in *mod-5* mutants (Figure 3, a and b). These results




FIGURE 3.—Action of fluoxetine and 5-HT on the ACh, GABA, and glutamate systems. (a) Aldicarb-induced paralysis of animals pretreated with 5-HT or fluoxetine and without pretreatment. Left, the percentage of worms paralyzed after 60 min of exposure to aldicarb. Right, the time course of aldicarb-induced paralysis. The error bars indicate SEM ($n > 3$ replicates). Different letters represent a significance difference (one-way ANOVA, $P < 0.05$). (b) Fluoxetine downregulates *ACh::gfp* in WT and *mod-5* mutant animals. Left, photomicrographs of *ACh::gfp* expression in animals untreated and treated with fluoxetine (0.5 mg/ml, 24 hr). Right, intensity of *ACh::gfp* in L4 animals without and with fluoxetine treatment was quantified by measuring the fluorescence in 9th and 10th neurons from the anterior (indicated in the photomicrographs by arrows) in individual animals. Each bar represents three independent experiments \pm SEM. *** $P < 0.001$, Student's *t*-test. (c and d) Fluoxetine sensitivity of ACh, GABA, and glutamate mutants. Fluoxetine sensitivities were measured as described in Figure 2d. Each bar represents three independent experiments \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, compared to WT, Student's *t*-test. (e and f) *UNC-49::GFP* expression in WT animals treated with 5-HT and fluoxetine. (e) Quantification of the fluorescence within an area of $50 \times 5 \mu\text{m}$ at the loco-

motory NMJs (as depicted in the photomicrograph). The average intensity in fluoxetine-treated animals is normalized to that of untreated animals. The experiment was performed six times. The results represent one set of blinded experiments (see Figure 6). * $P < 0.05$. (f) *UNC-49::GFP* was increased in the head region. Note that the fluorescence in animals treated with fluoxetine was higher than that in those treated with 5-HT. In contrast, *UNC-49::GFP* was reduced following 2 hr of treatment with 6 mM of the GABA agonist muscimol, which is consistent with ligand-induced internalization of GABA α receptor in mammalian systems (KITTLER *et al.* 2002).

indicate that the drug treatments did not damage the ACh neurons. Rather, both 5-HT and fluoxetine may reduce ACh signaling at the body-wall NMJs and the downregulation of *cha-1* and *unc-17* could account for

part of the fluoxetine effect; however, this action of fluoxetine is independent of MOD-5/SERT.

An *unc-29* loss-of-function mutant was hypersensitive to fluoxetine-induced paralysis, although a *cha-1* reduction-

of-function allele did not significantly alter fluoxetine sensitivity (Figure 3c). The *slo-1* BK potassium channel gain-of-function allele *ky399*, which reduced ACh release (DAVIES *et al.* 2003), was hypersensitive to fluoxetine in the paralysis assay (Figure 3d). Conversely, a *slo-1* loss-of-function allele and a mutant of the negative ACh neurotransmission regulator *tom-1* both exhibited an increase in ACh neurotransmission (WANG *et al.* 2001; GRACHEVA *et al.* 2006) and were both more resistant to fluoxetine as compared to WT (Figure 3d). These data suggest a model in which 5-HT signaling inhibits ACh neurotransmission and a deficit in ACh signaling may facilitate muscle relaxation following 5-HT and fluoxetine treatments.

We next examined GABAergic neurons. Since GABA is the major inhibitory input to the body-wall muscles, 5-HT and fluoxetine could cause muscle relaxation by increasing GABA signaling. 5-HT and fluoxetine did not produce an appreciable change in the expression of a GFP reporter for the GABA biosynthesis enzyme glutamic acid decarboxylase *unc-25* (data not shown). However, the GFP-tagged GABA_A receptor protein UNC-49 (UNC-49::GFP) was significantly increased at the body-wall NMJs (Figure 3e) and in the head muscles in animals treated with 5-HT or fluoxetine, with the fluorescence level higher in animals treated with fluoxetine (Figure 3f). If increased UNC-49 activity were responsible for the paralytic effect of fluoxetine, we would expect *unc-49* mutants to be more resistant to fluoxetine. However, both *unc-25* and *unc-49* mutants were hypersensitive to fluoxetine in the paralysis assay (Figure 3c). Thus, the increase in UNC-49 expression cannot account for paralysis induced by fluoxetine.

We also analyzed the relation of glutamate neurotransmission to fluoxetine sensitivity. Glutamate neurotransmission produces fast inhibitory inputs to the locomotory circuit (JORGENSEN 2005). Glutamate receptors have been detected in the locomotory command interneurons and the motor neurons (HART *et al.* 1995; DENT *et al.* 1997, 2000). Glutamate neurotransmission is thought to function as a pattern generator by regulating reciprocal inhibition between the forward and the backward command neurons (CHALFIE *et al.* 1985; ZHENG *et al.* 1999; BROCKIE *et al.* 2001), and excessive glutamate signaling may disrupt the neuronal circuitry, resulting in a cessation of movement (YATES *et al.* 2003). The *eat-4* glutamate transporter is implicated in glutamate neurotransmission (LEE *et al.* 1999; RAND *et al.* 2000). The AMPA type glutamate receptor *glr-1* is the best-studied *C. elegans* GLR receptor: it is expressed in the locomotory command interneurons (HART *et al.* 1995; MARICQ *et al.* 1995) and controls duration and direction of the movement (ZHENG *et al.* 1999). We did not detect a significant change in the expression and localization of the GFP-tagged EAT-4 protein (EAT4::GFP) and GLR-1 protein (GLR-1::GFP) in animals treated with 5-HT or fluoxetine (data not

shown, see below). But, mutants of *eat-4* and *glr-1* were more resistant to fluoxetine-induced paralysis compared to WT animals (Figure 3c).

Collectively, these experiments demonstrated a complex of interactions between fluoxetine treatment and synaptic functions of ACh, GABA, and glutamate. The downregulation of *ACh::gfp* and the upregulation of UNC-49::GFP indicate that fluoxetine produces distinctive effects on different neurotransmitter systems.

5-HT receptors SER-7 and SER-5 antagonistically regulate fluoxetine sensitivity: While the common effects of 5-HT and fluoxetine on MYO-3::GFP and the neuronal markers were suggestive of fluoxetine actions on 5-HT targets in the locomotory system, our analyses of the *mod-5* mutants showed that the fluoxetine effects were largely independent of MOD-5/SERT function (Figures 2d and 3, a and b). To gain more insights into the molecular mechanisms by which fluoxetine regulates synaptic functions and the relation to 5-HT, we took advantage of available deletion mutants of predicted 5-HT receptors and tested their ability to block fluoxetine-induced paralysis. None of tested 5-HT receptor mutants showed obvious defects in locomotion *per se*. Sensitivity to fluoxetine-induced paralysis was not significantly changed in mutants of *mod-1* (two alleles), *ser-3* (three alleles), *ser-4*, *T02E9*, and *C24A8.1* (data not shown). The *ser-1(ok512)* allele modestly slowed down paralysis (Figure S2). By contrast, three alleles of *ser-7*, which is most related to the mammalian 5-HT₇ receptor (HOBSON *et al.* 2006), were all significantly resistant to fluoxetine-induced paralysis compared to WT animals (Figure 4a, Figure S2). The *ser-1;ser-7* double mutant did not show stronger resistance than the *ser-7* single mutant, as measured after 40 min (Figure S2) and 24 hr (Student's *t*-test, $P = 0.13$, $n > 3$ replicates) of exposure to fluoxetine. Transgenic expression of the WT *ser-7* gene restored fluoxetine sensitivity of the *ser-7* mutants (Figure 4a), indicating that SER-7 function mediates this fluoxetine action. However, the *ser-7* mutants were not completely resistant to fluoxetine-induced paralysis, although all three *ser-7* alleles are deletion mutations predicted to be functional null (HOBSON *et al.* 2006). It is possible that fluoxetine could influence other, SER-7-independent functions in the locomotory circuit.

To determine whether SER-7 specifically mediates fluoxetine action or is a target shared by SSRIs, we analyzed two other SSRIs, sertraline (Zoloft) and escitalopram (Lexapro, Cipralox). Both sertraline and escitalopram induced paralysis in *C. elegans*, and the *ser-7* mutants were more resistant than WT (Figure 4b).

In contrast to the *ser-7* mutants, two *ser-5* deletion alleles both predicted to be functional null (HARRIS *et al.* 2009) were both hypersensitive to fluoxetine-induced paralysis compared to WT (Figure 4c). The *ser-5* mutants were also hypersensitive to inhibition of locomotion by 5-HT (Figure S3). Interestingly, two trans-




FIGURE 4.—SSRI-induced paralysis in *ser-5* and *ser-7* mutants. Larval stage four (L4) worms were incubated for 24 hr in liquid media supplemented with a drug: 0.5 mg/ml fluoxetine (a and d); 0.5 mg/ml fluoxetine, 0.25 mg/ml sertraline, and 2.25 mg/ml escitalopram (b); and 0.25 mg/ml fluoxetine (c). Drug sensitivities were calculated as described in Figure 2d. The values of the mutants are normalized to that of WT assayed in parallel. Two transgenic lines each for *Ex[ser-7(+)]* and *Ex[ser-5(+)]* were assayed. Each bar represents at least three independent experiments \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, Student's *t*-test.

genic arrays of the WT *ser-5* gene, *Ex[ser-5(+)]*, not only reversed the hypersensitivity of the *ser-5* mutant, but also conferred resistance to fluoxetine in both *ser-5* and WT backgrounds (Figure 4, c and d). These results suggest that SER-5 activity antagonizes the inhibitory effects of fluoxetine.

We further tested genetic interaction between *ser-7* and *ser-5*. The *ser-5;ser-7* double mutant was more resistant to fluoxetine compared to WT, although the resistance was slightly weaker than that of the *ser-7* single mutant (Figure 4d). Overexpression of SER-5 further enhanced resistance to fluoxetine in *ser-7* mutants (Figure 4d). Taken together, these results suggest that SER-5 signaling and SER-7 signaling antagonistically regulate fluoxetine action on the locomotory circuit.

Mutations in *ser-7* do not disrupt fluoxetine actions on the ACh and GABA systems: We asked whether SER-7 is required for fluoxetine to regulate synaptic functions in the locomotory system. Two experimental results indicate that the action of fluoxetine on ACh neurotransmission is unaffected in the absence of SER-7 (Figure 5). First, fluoxetine inhibited aldicarb sensitivity in the *ser-7* mutants as in WT animals (Figure 5a). Second, fluoxetine reduced *ACh::gfp* expression in the *ser-7* mutants (Figure 5b).

SER-7 is also not required for fluoxetine action on the GABA system (Figure 6). Fluoxetine increased UNC-49::GFP abundance in *ser-7* mutants as in WT animals (Figure 6a). Furthermore, if SER-7 acts in the GABA signaling pathway, a double mutant of *ser-7* and GABA synthesis mutant *unc-25* would be either hypersensitive

to fluoxetine as is the *unc-25* mutant or resistant to fluoxetine as is the *ser-7* mutant. In contrast, we found that the fluoxetine sensitivity of the *ser-7; unc-25* double mutant was in between that of the two single mutants (Figure 6b). Collectively, the data suggest that SER-7 regulates the activity of the locomotory system via a mechanism other than ACh and GABA.

SER-5 and SER-7 act in the same pathway as GLR-1 to regulate fluoxetine sensitivity: We also explored the relation of SER-5 and SER-7 to glutamate neurotransmission. GLR-1::GFP is expressed in puncta along the axons of the locomotory command neurons extending the full length of the ventral nerve cord, each punctum corresponding to a single synapse, and the density of GLR-1 synapses along the ventral cord is almost invariable between animal and animal (RONGO *et al.* 1998). Although GFP intensity of individual puncta was not significantly changed (data not shown), the number of GLR-1::GFP synapses was reduced in *ser-7* mutants, compared to age-matched WT animals (Figure 7a).

To explore the functional relationship between glutamate neurotransmission and *ser-7*, we generated double mutants. Single mutants of *ser-7*, *glr-1*, and *eat-4*, as well as double mutants of *ser-7;glr-1* and *ser-7;eat-4*, all exhibited similar resistance to fluoxetine (Figure 7b). To test if glutamate signaling is a downstream target of SER-7, we attempted to overexpress SER-7. Expressing the *ser-7(+)* transgene in a WT background caused hypersensitivity to fluoxetine-induced paralysis (Figure 7b). However, the *glr-1* mutant expressing the same *ser-7(+)* transgene was as resistant to fluoxetine as the *glr-1*




FIGURE 5.—Action of fluoxetine and 5-HT on ACh in *ser-7* mutants. (a) Aldicarb-induced immobility of animals pretreated with 5-HT (5 mg/ml) or fluoxetine (0.5 mg/ml) or without pretreatment. The values of the mutants and pretreated animals are normalized to that of WT animals without pretreatment. (b) Fluoxetine downregulates *ACh::gfp* in WT and *ser-7* mutant animals. Intensity of the fluorescence in the 9th and 10th neurons from the anterior (as shown in Figure 3b) was quantified. The values of WT animals treated with fluoxetine (0.5 mg/ml, 24 hr) and the *ser-7(tm1325)* mutant untreated and treated with fluoxetine are normalized to that of untreated WT assayed on the same day. Each bar represents at least three replicate experiments \pm SEM. *** $P < 0.001$, Student's *t*-test.

mutant (Figure 7b), suggesting that GLR-1 activity is required for SER-7 to promote paralysis by fluoxetine. Furthermore, the fluoxetine sensitivity of the *ser-5;glr-1* double mutant was similar to that of the *glr-1* single mutant (Figure 7b), suggesting that the fluoxetine hypersensitivity of the *ser-5* mutants also depends on GLR-1 function.

Fluoxetine binds to SER-7: We tested whether fluoxetine directly binds SER-7 expressed heterologously in mammalian COS-7 cells, using a standard approach (PERT *et al.* 1973). One group of us previously established that the membrane of COS-7 cells transiently expressing the SER-7b isoform exhibits saturable specific binding to the 5-HT-like ligand [3 H]LSD (HOBSON *et al.* 2003, 2006). 5-HT could efficiently displace [3 H]LSD binding, while dopamine, histamine, tyramine, and octopamine did not show a significant affinity

to SER-7b (HOBSON *et al.* 2003). Like 5-HT, fluoxetine effectively competed [3 H]LSD for binding SER-7b expressed in the COS-7 cells with IC_{50} of $0.42 \pm 0.03 \mu M$ (Figure 8), suggesting that fluoxetine can directly bind to SER-7.


DISCUSSION

SSRIs are useful in the treatment of a wide spectrum of behavioral and psychiatric disorders. Increasingly it has become clear that many of these disorders are inheritable, with each involving multiple genetic loci contributing small and additive effects to a complex of symptomatic traits. While the action of SSRIs as SERT inhibitors is well established, the cellular and molecular mechanisms by which SSRIs alleviate specific symptoms are poorly understood. In this study, we identified two additional aspects of fluoxetine action on the serotonergic system through genetic analyses in *C. elegans*. We showed that fluoxetine eliminated 5-HT in specific neurons. These neurons absorb extracellular 5-HT via MOD-5/SERT but do not synthesize it. Furthermore, we demonstrated that fluoxetine directly targets G-protein-coupled 5-HT receptors to regulate a behavioral circuit. These findings could shed some light on therapeutic effects of fluoxetine and our understanding of 5-HT neurotransmission.

The effects of fluoxetine are multifactorial: There is an ongoing debate on the effects of SSRIs on 5-HT signaling. In rodents, administration of fluoxetine immediately induces a significant increase in the extracellular levels of 5-HT in the brain (SCHATZBERG and NEMEROFF 2004). Intriguingly, a SERT knockout mouse showed reduced brain 5-HT (BENGEL *et al.* 1998). Furthermore, an allele of reduced SERT expression is found in patients suffering bipolar disorder and autism (BARTLETT *et al.* 2005; BRUNE *et al.* 2006; BARNETT and SMOLLER 2009). In this study, we identified two distinctive populations of serotonergic neurons in *C. elegans*: the NSM, ADF, and HSN neurons producing 5-HT and the RIH and AIM neurons absorbing 5-HT from extracellular space but unable to synthesize it. We showed that fluoxetine and imipramine, like the *mod-5/SERT* mutations, eliminated 5-HT in the AIM and RIH neurons.

5-HT-absorbing neurons are likely an evolutionary conserved feature of the serotonergic system. In rodents SERT is expressed in a range of CNS neurons that do not express 5-HT biosynthesis enzymes (GASPAR *et al.* 2003). In particular, SERT is expressed transiently in the thalamus and in all primary sensory areas including visual, auditory, and somatosensory areas in early postnatal rodents (D'AMATO *et al.* 1987; BENGEL *et al.* 1997; HANSSON *et al.* 1999) and in nonmonoaminergic neurons in developing human cerebral cortex (VERNEY *et al.* 2002).

How does blocking SERT function in 5-HT-absorbing neurons possibly affect 5-HT signaling? One possible



fluoxetine. * $P < 0.05$, Student's *t*-test. (b) Fluoxetine-induced paralysis. Fluoxetine sensitivity was calculated as described in Figure 2d. Each bar represents three replicate experiments \pm SEM. ** $P < 0.01$, *** $P < 0.001$. There is no significant difference between WT and *ser-7; unc-25* ($P > 0.9$, Student's *t*-tests).

role of 5-HT-absorbing neurons could be to scavenge 5-HT spillover, thereby enhancing the specificity of the signaling of 5-HT transmission. Indeed, the axons of the AIM and RIH neurons are close to the axons of ADF and NSM (WHITE *et al.* 1986). This model is consistent with published studies showing that *mod-5*/SERT-null mutants exhibit certain behavioral phenotypes of increased 5-HT signaling (RANGANATHAN *et al.* 2001). However, it is possible that 5-HT-absorbing neurons use 5-HT as borrowed transmitter, serving as “relay stations” to pass 5-HT from the original neuronal sources to distant targets. The support for this idea is the presence of the vesicular monoamine transporter (VMAT) CAT-1 in the

AIM and RIH neurons (DUERR *et al.* 1999; SZE *et al.* 2002), indicating the capability to store imported 5-HT in the synaptic vesicles. If this model is correct, that would imply that fluoxetine reduces 5-HT singling mediated by these neurons.

Our genetic and biochemical analyses indicate that fluoxetine acts in part by targeting 5-HT receptors. This result is consistent with the biochemical studies showing that fluoxetine and other SSRIs bind to many subtypes of mammalian 5-HT receptors (KROEZE and ROTH 1998). Interestingly, our data suggest that the actions of fluoxetine and 5-HT are not identical. Fluoxetine appeared to produce greater effects than exogenous




FIGURE 7.—Genetic interaction between *glr-1*, *ser-5*, and *ser-7*. (a) Quantification of GLR-1::GFP puncta in WT and *ser-7(tm1325)* animals. GLR-1::GFP is localized to the punctate structure along the ventral nerve cord (RONGO *et al.* 1998). Individual GLR-1::GFP puncta in 1-day-old adults, genotype blinded, were counted under a fluorescence microscope, $N = 15$ per strain. The P -value is indicated on the top of the bar (Student's *t*-test). (b) Fluoxetine-induced paralysis. The percentage of paralyzed animals, normalized to that of WT assayed on the same day, is shown for the mutants and transgenic animals. Each bar represents three replicate experiments \pm SEM. The differences between *glr-1* and *ser-5; glr-1* and the differences between *glr-1; ser-7; glr-1*, and *glr-1; Ex[ser-7(+)]* are not significant ($P > 0.1$, Student's *t*-test).




FIGURE 8.—Fluoxetine binds to SER-7. The membrane fraction of COS-7 cells transiently expressing the SER-7b isoform was incubated with 10 nM [3 H]LSD alone or in the presence of 5-HT or fluoxetine at the indicated concentrations. The data are representative of at least three experiments, each performed in triplicate. Each point is the mean \pm SEM.

5-HT on examined neuronal markers. Furthermore, animals treated with serotonin but not with fluoxetine could recover and resume locomotion. The recovery is unlikely due to 5-HT being unstable (Figure S4), suggesting animals can adapt to 5-HT but not to fluoxetine. It will be interesting to define the binding sites of 5-HT and SSRI on SER-7 in the future.

It has been established that fluoxetine, but not 5-HT, can induce *C. elegans* nose contraction, demonstrating that fluoxetine can target genes outside of 5-HT signaling pathways to regulate behavior (CHOY and THOMAS 1999; CHOY *et al.* 2006). However, we found that the *nrf-6* mutant, which is strongly resistant to fluoxetine-induced nose contraction (CHOY and THOMAS 1999), did not affect fluoxetine-induced paralysis (Figure 3c). Thus, systematic characterization of fluoxetine effects on individual behaviors in *C. elegans* may identify its gene targets in 5-HT signaling pathways, as well as the genes mediating other aspects of SSRI actions.

Interaction between 5-HT and other neurotransmitters: Our analysis of GFP reporters revealed that fluoxetine influences discrete steps of synaptic transmission of ACh, GABA, and glutamate. Regulation of synaptic function by 5-HT signaling is thought to play myriad roles in the modulation of emotion, cognition, and motor behavior in mammals (MILLAN 2003). Increased central cholinergic tone induces depression in humans (JANOWSKY and OVERSTREET 1990). Fluoxetine is useful in the treatment of congenital myasthenic syndromes, which is characterized by increased ACh neurotransmission at NMJs (HARPER *et al.* 2003; COLOMER *et al.* 2006).

Our genetic analyses suggest that SER-5 and SER-7 act antagonistically to regulate GLR-1 signaling in the locomotory circuit. Opposing 5-HT receptors have been

found to modulate other behaviors in *C. elegans*. For example, *ser-7* and *ser-1* stimulate egg laying in opposition to *ser-4* (HAPIAK *et al.* 2009), and *ser-1* and *ser-4* antagonistically regulate aging (MURAKAMI and MURAKAMI 2007). However, SER-5 and SER-7 have not been detected in neurons directly involved in locomotion (TSALIK *et al.* 2003; CARRE-PIERRAT *et al.* 2006; HARRIS *et al.* 2009) and *ser-7* mutants do not exhibit defects in GLR-1-mediated nose-touch response (data not shown). It is likely that SER-7 and SER-5 are not required for glutamate neurotransmission but act indirectly to influence its activity in the locomotory circuit. Interestingly, fluoxetine, imipramine, and several other antidepressants can increase AMPA receptor phosphorylation in the mouse brain (SVENNINGSSON *et al.* 2002, 2007; DU *et al.* 2007).

We showed that loss of *ser-7* function did not block fluoxetine action on ACh and GABA neurotransmission in the locomotory circuit. It has been reported that the G-protein-coupled 5-HT receptors SER-1 (DERNOVICI *et al.* 2007) and SER-4 (GOVORUNOVA *et al.* 2010) are also involved in the control of locomotion. *ser-1* is predicted to regulate the locomotory circuit indirectly through interneurons (DERNOVICI *et al.* 2007). Therefore, in *C. elegans*, as in mammals (LUCKI 1992), 5-HT is probably not required for behavior to occur. Rather it may act via distinct 5-HT receptors in multiple cellular sites to coordinate synaptic functions of behavioral circuits.

We thank R. Horvitz, E. Jorgensen, J. McGhree, J. Rand, and the Caenorhabditis Genetics Center for worm strains and the *C. elegans* Knockout Consortium for deletion mutants. We specially thank Shohei Mitani for 5-HT receptor deletion alleles. We are grateful to R. Patel for assistance in some behavioral assays. This work was supported by a Marie Curie Outgoing International Fellowship (to C.M.D.), an award from the Department of Defense Autism Spectrum Disorder Research Program, and grants from the National Institute of Mental Health (to J.Y.S.).

LITERATURE CITED

- ALFONSO, A., K. GRUNDAHL, J. R. MCMANUS, J. M. ASBURY and J. B. RAND, 1994 Alternative splicing leads to two cholinergic proteins in *Caenorhabditis elegans*. *J. Mol. Biol.* **241**: 627–630.
- AVERY, L., and H. R. HORVITZ, 1990 Effects of starvation and neuroactive drugs on feeding in *Caenorhabditis elegans*. *J. Exp. Zool.* **253**: 263–270.
- BARNETT, J. H., and J. W. SMOLLER, 2009 The genetics of bipolar disorder. *Neuroscience* **164**: 331–343.
- BARTLETT, C. W., N. GHARANI, J. H. MILLONIG and L. M. BRZUSTOWICZ, 2005 Three autism candidate genes: a synthesis of human genetic analysis with other disciplines. *Int. J. Dev. Neurosci.* **23**: 221–234.
- BENGEL, D., O. JOHREN, A. M. ANDREWS, A. HEILS, R. MOSSNER *et al.*, 1997 Cellular localization and expression of the serotonin transporter in mouse brain. *Brain Res.* **778**: 338–345.
- BENGEL, D., D. L. MURPHY, A. M. ANDREWS, C. H. WICHEMS, D. FELTNER *et al.*, 1998 Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (“Ecstasy”) in serotonin transporter-deficient mice. *Mol. Pharmacol.* **53**: 649–655.
- BLAKELY, R. D., H. E. BERSON, R. T. FREMEAUX, JR., M. G. CARON, M. M. PEEK *et al.*, 1991 Cloning and expression of a functional serotonin transporter from rat brain. *Nature* **354**: 66–70.
- BRENNER, S., 1974 The genetics of *Caenorhabditis elegans*. *Genetics* **77**: 71–94.

- BROCKIE, P. J., J. E. MELLEM, T. HILLS, D. M. MADSEN and A. V. MARICQ, 2001 The *C. elegans* glutamate receptor subunit NMR-1 is required for slow NMDA-activated currents that regulate reversal frequency during locomotion. *Neuron* **31**: 617–630.
- BRUNE, C. W., S. J. KIM, J. SALT, B. L. LEVENTHAL, C. LORD *et al.*, 2006 5-HTTLPR genotype-specific phenotype in children and adolescents with autism. *Am. J. Psychiatry* **163**: 2148–2156.
- CARNELL, L., J. ILLI, S. W. HONG and S. L. MCINTIRE, 2005 The G-protein-coupled serotonin receptor SER-1 regulates egg laying and male mating behaviors in *Caenorhabditis elegans*. *J. Neurosci.* **25**: 10671–10681.
- CARRE-PIERRAT, M., D. BAILLIE, R. JOHNSEN, R. HYDE, A. HART *et al.*, 2006 Characterization of the *Caenorhabditis elegans* G protein-coupled serotonin receptors. *Invert. Neurosci.* **6**: 189–205.
- CHALFIE, M., J. E. SULSTON, J. G. WHITE, E. SOUTHGATE, J. N. THOMSON *et al.*, 1985 The neural circuit for touch sensitivity in *Caenorhabditis elegans*. *J. Neurosci.* **5**: 956–964.
- CHOY, R. K., and J. H. THOMAS, 1999 Fluoxetine-resistant mutants in *C. elegans* define a novel family of transmembrane proteins. *Mol. Cell* **4**: 143–152.
- CHOY, R. K., J. M. KEMNER and J. H. THOMAS, 2006 Fluoxetine-resistance genes in *Caenorhabditis elegans* function in the intestine and may act in drug transport. *Genetics* **172**: 885–892.
- COLOMER, J., J. S. MULLER, A. VERNET, A. NASCIMENTO, M. PONS *et al.*, 2006 Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine. *Neuromuscul. Disord.* **16**: 329–333.
- D'AMATO, R. J., M. E. BLUE, B. L. LARGENT, D. R. LYNCH, D. J. LEDBETTER *et al.*, 1987 Ontogeny of the serotonergic projection to rat neocortex: transient expression of a dense innervation to primary sensory areas. *Proc. Natl. Acad. Sci. USA* **84**: 4322–4326.
- DAVIES, A. G., J. T. PIERCE-SHIMOMURA, H. KIM, M. K. VANHOVEN, T. R. THIELE *et al.*, 2003 A central role of the BK potassium channel in behavioral responses to ethanol in *C. elegans*. *Cell* **115**: 655–666.
- DEMPSEY, C. M., S. M. MACKENZIE, A. GARGUS, G. BLANCO and J. Y. SZE, 2005 Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT receptor signaling to modulate *Caenorhabditis elegans* egg-laying behavior. *Genetics* **169**: 1425–1436.
- DENT, J. A., M. W. DAVIS and L. AVERY, 1997 avt-15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in *Caenorhabditis elegans*. *EMBO J.* **16**: 5867–5879.
- DENT, J. A., M. M. SMITH, D. K. VASSILATIS and L. AVERY, 2000 The genetics of ivermectin resistance in *Caenorhabditis elegans*. *Proc. Natl. Acad. Sci. USA* **97**: 2674–2679.
- DERNOVICI, S., T. STARC, J. A. DENT and P. RIBEIRO, 2007 The serotonin receptor SER-1 (5HT2c) contributes to the regulation of locomotion in *Caenorhabditis elegans*. *Dev. Neurobiol.* **67**: 189–204.
- DU, J., K. SUZUKI, Y. WEI, Y. WANG, R. BLUMENTHAL *et al.*, 2007 The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. *Neuropsychopharmacology* **32**: 793–802.
- DUERR, J. S., D. L. FRISBY, J. GASKIN, A. DUKE, K. ASERMELY *et al.*, 1999 The cat-1 gene of *Caenorhabditis elegans* encodes a vesicular monoamine transporter required for specific monoamine-dependent behaviors. *J. Neurosci.* **19**: 72–84.
- EISENSAMER, B., G. RAMMES, G. GIMPL, M. SHAPA, U. FERRARI *et al.*, 2003 Antidepressants are functional antagonists at the serotonin type 3 (5-HT₃) receptor. *Mol. Psychiatry* **8**: 994–1007.
- FINK, K. B., and M. GOTHERT, 2007 5-HT receptor regulation of neurotransmitter release. *Pharmacol. Rev.* **59**: 360–417.
- FUKUSHIGE, T., M. J. HENDZEL, D. P. BAZETT-JONES and J. D. MCGHEE, 1999 Direct visualization of the elt-2 gut-specific GATA factor binding to a target promoter inside the living *Caenorhabditis elegans* embryo. *Proc. Natl. Acad. Sci. USA* **96**: 11883–11888.
- GASPAR, P., O. CASES and L. MAROTEAUX, 2003 The developmental role of serotonin: news from mouse molecular genetics. *Nat. Rev. Neurosci.* **4**: 1002–1012.
- GOVORUNOVA, E. G., M. MOUSSAIF, A. KULLYEV, K. C. NGUYEN, T. V. McDONALD *et al.*, 2010 A homolog of FHM2 is involved in modulation of excitatory neurotransmission by serotonin in *C. elegans*. *PLoS One* **5**: e10368.
- GRACHEVA, E. O., A. O. BURDINA, A. M. HOLGADO, M. BERTHELOT-GROSJEAN, B. D. ACKLEY *et al.*, 2006 Tomosyn inhibits synaptic vesicle priming in *Caenorhabditis elegans*. *PLoS Biol.* **4**: e261.
- HANSSON, S. R., E. MEZEY and B. J. HOFFMAN, 1999 Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo. *Neuroscience* **89**: 243–265.
- HAPIAK, V. M., R. J. HOBSON, L. HUGHES, K. SMITH, G. HARRIS *et al.*, 2009 Dual excitatory and inhibitory serotonergic inputs modulate egg laying in *Caenorhabditis elegans*. *Genetics* **181**: 153–163.
- HARE, E. E., and C. M. LOER, 2004 Function and evolution of the serotonin-synthetic bas-1 gene and other aromatic amino acid decarboxylase genes in *Caenorhabditis*. *BMC Evol. Biol.* **4**: 24.
- HARPER, C. M., T. FUKODOME and A. G. ENGEL, 2003 Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. *Neurology* **60**: 1710–1713.
- HARRIS, G. P., V. M. HAPIAK, R. T. WRAGG, S. B. MILLER, L. J. HUGHES *et al.*, 2009 Three distinct amine receptors operating at different levels within the locomotory circuit are each essential for the serotonergic modulation of chemosensation in *Caenorhabditis elegans*. *J. Neurosci.* **29**: 1446–1456.
- HART, A. C., S. SIMS and J. M. KAPLAN, 1995 Synaptic code for sensory modalities revealed by *C. elegans* GLR-1 glutamate receptor. *Nature* **378**: 82–85.
- HOBSON, R. J., J. GENG, A. D. GRAY and R. W. KOMUNIECKI, 2003 SER-7b, a constitutively active Galphas coupled 5-HT₇-like receptor expressed in the *Caenorhabditis elegans* M4 pharyngeal motoneuron. *J. Neurochem.* **87**: 22–29.
- HOBSON, R. J., V. M. HAPIAK, H. XIAO, K. L. BUEHRER, P. R. KOMUNIECKI *et al.*, 2006 SER-7, a *Caenorhabditis elegans* 5-HT₇-like receptor, is essential for the 5-HT stimulation of pharyngeal pumping and egg laying. *Genetics* **172**: 159–169.
- HOFFMAN, B. J., S. R. HANSSON, E. MEZEY and M. PALKOVITS, 1998 Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. *Front. Neuroendocrinol.* **19**: 187–231.
- HOFFMAN, B. J., E. MEZEY and M. J. BROWNSTEIN, 1991 Cloning of a serotonin transporter affected by antidepressants. *Science* **254**: 579–580.
- JANOWSKY, D. S., and D. H. OVERSTREET, 1990 Cholinergic dysfunction in depression. *Pharmacol. Toxicol.* **66** (Suppl. 3): 100–111.
- JORGENSEN, E. M., 2005 GABA (August 31, 2005), *WormBook*, ed. THE *C. ELEGANS* RESEARCH COMMUNITY, *WormBook*, doi/10.1895/wormbook.1.14.1, <http://www.wormbook.org>.
- KANDEL, E. R., 2001 The molecular biology of memory storage: a dialogue between genes and synapses. *Science* **294**: 1030–1038.
- KITTLER, J. T., K. MCAINSH and S. J. MOSS, 2002 Mechanisms of GABA_A receptor assembly and trafficking: implications for the modulation of inhibitory neurotransmission. *Mol. Neurobiol.* **26**: 251–268.
- KROEZE, W. K., and B. L. ROTH, 1998 The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. *Biol. Psychiatry* **44**: 1128–1142.
- LEBRAND, C., O. CASES, R. WEHRLE, R. D. BLAKELY, R. H. EDWARDS *et al.*, 1998 Transient developmental expression of monoamine transporters in the rodent forebrain. *J. Comp. Neurol.* **401**: 506–524.
- LEE, R. Y., E. R. SAWIN, M. CHALFIE, H. R. HORVITZ and L. AVERY, 1999 EAT-4, a homolog of a mammalian sodium-dependent inorganic phosphate cotransporter, is necessary for glutamatergic neurotransmission in *Caenorhabditis elegans*. *J. Neurosci.* **19**: 159–167.
- LEWIS, J. A., C. H. WU, J. H. LEVINE and H. BERG, 1980 Levamisole-resistant mutants of the nematode *Caenorhabditis elegans* appear to lack pharmacological acetylcholine receptors. *Neuroscience* **5**: 967–989.
- LUCKI, I., 1992 5-HT₁ receptors and behavior. *Neurosci. Biobehav. Rev.* **16**: 83–93.
- MAHONEY, T. R., S. LUO and M. L. NONET, 2006 Analysis of synaptic transmission in *Caenorhabditis elegans* using an aldicarb-sensitivity assay. *Nat. Protoc.* **1**: 1772–1777.
- MARICQ, A. V., E. PECKOL, M. DRISCOLL and C. I. BARGMANN, 1995 Mechanosensory signalling in *C. elegans* mediated by the GLR-1 glutamate receptor. *Nature* **378**: 78–81.
- MILLAN, M. J., 2003 The neurobiology and control of anxious states. *Prog. Neurobiol.* **70**: 83–244.

- MURAKAMI, H., and S. MURAKAMI, 2007 Serotonin receptors antagonistically modulate *Caenorhabditis elegans* longevity. *Aging Cell* **6**: 483–488.
- NI, Y. G., and R. MILEDI, 1997 Blockage of 5HT_{2C} serotonin receptors by fluoxetine (Prozac). *Proc. Natl. Acad. Sci. USA* **94**: 2036–2040.
- NURRISH, S., L. SEGALAT and J. M. KAPLAN, 1999 Serotonin inhibition of synaptic transmission: Galpha(0) decreases the abundance of UNC-13 at release sites. *Neuron* **24**: 231–242.
- PERT, C. B., G. PASTERNAK and S. H. SNYDER, 1973 Opiate agonists and antagonists discriminated by receptor binding in brain. *Science* **182**: 1359–1361.
- RAND, J. B., J. S. DUERR and D. L. FRISBY, 2000 Neurogenetics of vesicular transporters in *C. elegans*. *FASEB J.* **14**: 2414–2422.
- RANGANATHAN, R., E. R. SAWIN, C. TRENT and H. R. HORVITZ, 2001 Mutations in the *Caenorhabditis elegans* serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine. *J. Neurosci.* **21**: 5871–5884.
- REINER, D. J., D. WEINSHENKER and J. H. THOMAS, 1995 Analysis of dominant mutations affecting muscle excitation in *Caenorhabditis elegans*. *Genetics* **141**: 961–976.
- REINER, D. J., E. M. NEWTON, H. TIAN and J. H. THOMAS, 1999 Diverse behavioural defects caused by mutations in *Caenorhabditis elegans* unc-43 CaM kinase II. *Nature* **402**: 199–203.
- RONGO, C., C. W. WHITFIELD, A. RODAL, S. K. KIM and J. M. KAPLAN, 1998 LIN-10 is a shared component of the polarized protein localization pathways in neurons and epithelia. *Cell* **94**: 751–759.
- SCHATZBERG, A. F., and C. B. NEMEROFF, 2004 *The American Psychiatric Publishing Textbook of Psychopharmacology*. American Psychiatric Pub., Washington, DC.
- SVENNINGSSON, P., E. T. TZAVARA, J. M. WITKIN, A. A. FIENBERG, G. G. NOMIKOS *et al.*, 2002 Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). *Proc. Natl. Acad. Sci. USA* **99**: 3182–3187.
- SVENNINGSSON, P., H. BATEUP, H. QI, K. TAKAMIYA, R. L. HUGANIR *et al.*, 2007 Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. *Eur. J. Neurosci.* **26**: 3509–3517.
- SZE, J. Y., M. VICTOR, C. LOER, Y. SHI and G. RUVKUN, 2000 Food and metabolic signalling defects in a *Caenorhabditis elegans* serotonin-synthesis mutant. *Nature* **403**: 560–564.
- SZE, J. Y., S. ZHANG, J. LI and G. RUVKUN, 2002 The *C. elegans* POU-domain transcription factor UNC-86 regulates the tph-1 tryptophan hydroxylase gene and neurite outgrowth in specific serotonergic neurons. *Development* **129**: 3901–3911.
- TSALIK, E. L., T. NIACARIS, A. S. WENICK, K. PAU, L. AVERY *et al.*, 2003 LIM homeobox gene-dependent expression of biogenic amine receptors in restricted regions of the *C. elegans* nervous system. *Dev. Biol.* **263**: 81–102.
- VERNEY, C., C. LEBRAND and P. GASPARD, 2002 Changing distribution of monoaminergic markers in the developing human cerebral cortex with special emphasis on the serotonin transporter. *Anat. Rec.* **267**: 87–93.
- WANG, Z. W., O. SAIFEE, M. L. NONET and L. SALKOFF, 2001 SLO-1 potassium channels control quantal content of neurotransmitter release at the *C. elegans* neuromuscular junction. *Neuron* **32**: 867–881.
- WEINSHENKER, D., G. GARRIGA and J. H. THOMAS, 1995 Genetic and pharmacological analysis of neurotransmitters controlling egg laying in *C. elegans*. *J. Neurosci.* **15**: 6975–6985.
- WHITE, J. G., E. SOUTHGATE, J. N. THOMSON and S. BRENNER, 1986 The structure of the nervous system of the nematode *Caenorhabditis elegans*. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **314**: 1–340.
- YATES, D. M., V. PORTILLO and A. J. WOLSTENHOLME, 2003 The avermectin receptors of *Haemonchus contortus* and *Caenorhabditis elegans*. *Int. J. Parasitol.* **33**: 1183–1193.
- ZHANG, Y., H. LU and C. I. BARGMANN, 2005 Pathogenic bacteria induce aversive olfactory learning in *Caenorhabditis elegans*. *Nature* **438**: 179–184.
- ZHENG, Y., P. J. BROCKIE, J. E. MELLEM, D. M. MADSEN and A. V. MARICQ, 1999 Neuronal control of locomotion in *C. elegans* is modified by a dominant mutation in the GLR-1 ionotropic glutamate receptor. *Neuron* **24**: 347–361.

Communicating editor: P. C. PHILLIPS

GENETICS

Supporting Information

<http://www.genetics.org/cgi/content/full/genetics.110.118877/DC1>

A Genetic Survey of Fluoxetine Action on Synaptic Transmission in *Caenorhabditis elegans*

**Andrey Kullyev, Catherine M. Dempsey, Sarah Miller, Chih-Jen Kuan, Vera M. Hapiak,
Richard W. Komuniecki, Christine T. Griffin and Ji Ying Sze**

Copyright © 2010 by the Genetics Society of America
DOI: 10.1534/genetics.110.118877




FIGURE S1.—Photomicrographs of MYO-3::GFP in the body-wall muscle sarcomeres in *mod-5* and *tph-1* mutants. Animals were incubated for 60 min in S-medium containing 0.5 mg/ml fluoxetine and the drug-free controls. The inset in lower left panel shows branches crossing the muscle fibers, which were frequently observed in untreated *tph-1* mutants, but not in WT and *mod-5* mutant animals. One-day old adults were examined.




FIGURE S2.—The time course of fluoxetine-induced paralysis. The assay has been performed multiple times, and the data from one experiment are presented.




FIGURE S3.—Effects of 5-HT treatment on locomotion in WT, *ser-5* and *ser-7* mutant animals. One-day old animals were transferred onto NGM plates supplemented with 5 mg/ml 5HT (hatched bars) or without 5-HT (black bars) for 15 min. The number of body bends of individual animals was scored by continuously monitoring individual animals for 20 seconds. In the presence of 5-HT, locomotion of *ser-5* mutants was slower than that of WT ($p < 0.05$). However, the difference between WT and the *ser-7* mutant animals is not significant ($p > 0.05$). Student's t-test.




FIGURE S4.—Analysis of 5-HT stability in solution. The stability of 5-HT in solution was evaluated by testing its ability to induce egg laying in WT animals. 5-HT was dissolved in M9 buffer to give the final concentration of 5 mg/ml 5HT, and the solution was stored in dark at 20°C. To test the response to 5-HT, animals were placed individually into wells of a 96-well plate, with each containing 100 ml of M9 buffer or M9 buffer containing 5-HT. The number of eggs laid was scored after 60 min. Animals did not laid egg in M9 buffer (data not shown) (Trent *et al.* 1983). There is no significant difference in the number of eggs laid between animals incubated in the solution at these four time points ($p > 0.4$ Student's t-test).

Reference

Trent, C., N. Tsuing and H. R. Horvitz, 1983 Egg-laying defective mutants of the nematode *Caenorhabditis elegans*. *Genetics* 104: 619-647.